A eureka consortium of scientists from research institutions and 8 leading plant breeding/biotechnology companies will apply innovative molecular techniques to solve urgent quality problems in the most important european cereals.
Development of anti-cancer vaccines. The technology combines a promising tumour antigen with a powerful vaccine vector to provide a specific immunotherapy.
Acceleration and diversification of flavour formation in semi-hard cheeses, by controlling amino-acid catabolism with lactic acid bacteria (lab).
The structural knowledge of the mutated androgen receptor ligand binding domain and its complexes with agonists and antagonists should shed light on controlling proliferation of prostate cancer cells, thus facilitating drug design.
Based on cannabis metabolomics, cannabis smoke-analysis and advanced extraction techniques, tailor-made well-defined extractions will be made for different medical applications and new techniques for oral admin will be developed.
The fundamentals for a "natural" supply chain of fats will be developed. For this step change, chemical processes must be eliminated. This involves development of milder oil purification, application of enzymes and development of a new variety of sunflower.
Propionic acid bacteria (pab) are applied, together with other dairy bacteria, for development of a swiss flavour concentrate and for improvement of ripening of semi-hard cheeses. The focus is on (directing) routes of flavour formation by pab.
Use of the cheap and readily available 99m-tc as a radioisotope to perform tumour-specific metabolic diagnosis in patients with cancer.
Extending the capabilities of an innovative needle-free, single use injector to meet full customisation needs, very high volume manufacturing, minimum time to market delays and very high safety levels.
Fundamental research to develop the basis for a very accurate innovative tool for the selection of different meat and carcass quality measurements in pork production.